Research Analysts Issue Forecasts for ARTV FY2025 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Investment analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for shares of Artiva Biotherapeutics in a research note issued to investors on Monday, May 12th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will post earnings per share of ($3.04) for the year, down from their previous forecast of ($2.91). Cantor Fitzgerald currently has a "Overweight" rating and a $20.00 target price on the stock. The consensus estimate for Artiva Biotherapeutics' current full-year earnings is ($4.95) per share.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.15).

A number of other equities research analysts have also recently issued reports on ARTV. Wedbush restated an "outperform" rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a research note on Tuesday, March 25th. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Artiva Biotherapeutics in a research note on Wednesday, March 26th. Finally, Needham & Company LLC restated a "buy" rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a research note on Tuesday, April 8th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $20.40.

Artiva Biotherapeutics Stock Down 2.4%

Shares of NASDAQ ARTV opened at $2.05 on Wednesday. Artiva Biotherapeutics has a one year low of $1.78 and a one year high of $17.31. The business's fifty day moving average price is $3.08 and its 200-day moving average price is $6.73.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. bought a new stake in shares of Artiva Biotherapeutics during the fourth quarter valued at about $52,000. Wells Fargo & Company MN grew its stake in Artiva Biotherapeutics by 64.0% during the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company's stock valued at $87,000 after acquiring an additional 3,361 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in Artiva Biotherapeutics by 262.1% during the 4th quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company's stock worth $100,000 after acquiring an additional 7,151 shares during the period. Nuveen LLC purchased a new stake in Artiva Biotherapeutics in the 1st quarter worth approximately $144,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in Artiva Biotherapeutics by 26.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company's stock worth $165,000 after purchasing an additional 11,355 shares in the last quarter.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.